Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

sandoz d.o.o., maksimirska 120, zagreb, hrvatska - fingolimodklorid - kapsula, tvrda - urbroj: jedna tvrda kapsula sadrži 0,25 mg fingolimoda (u obliku fingolimodklorida)

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - virus pds 2242 virus / virus vcp1529 / vcp1533 virus / vcp3011 - imunomodulatori, žive virusne vakcine virusa influence konja - konji - aktivna imunizacija konja od četiri mjeseca ili starije od konjske gripe radi smanjenja kliničkih znakova i izlučivanja virusa nakon infekcije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - tipranavira - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - Аптивус, uvedeni zajedno s malom dozom ritonavir, prikazan je za kombinovanu антиретровирусной terapije hiv-1 infekcije u krajnje obučena odrasle i mlade od 12 godina i stariji sa virusom, otporna na mnoge proteaze ингибиторам . Аптивус treba koristiti samo kao dio aktivne antiretrovirusne kombinacije lijekova u bolesnika s nedostatkom drugih terapijskih mogućnosti. ovaj indeks se temelji na rezultatima druga faza iii studije u najvišoj mjeri osposobljeni za odrasle pacijente (prosječan broj 12 do антиретровирусными lijekovima) s virusa, otporna na ингибиторам proteaze i jedne faze ii studije posvećene proučavanju фармакокинетики, sigurnosti i učinkovitosti Аптивус uglavnom liječenje-iskusni mlade bolesnika u dobi od 12 do 18 godina. odlučivši započeti liječenje s Аптивус, uvedeni zajedno s malom dozom ritonavir, pažljivo razmatranje treba posvetiti povijesti liječenje pacijenta i prirode mutacije povezane s različitim posrednika. Генотипического ili фенотипического testiranja (ako postoje) i povijest liječenja treba koristiti Аптивус. početka liječenja treba uzeti u obzir kombinacije mutacija koje mogu negativno utjecati na virus se javlja odgovor na Аптивус, uvedeni zajedno s malom dozom ritonavir.

Europska Unija - hrvatski - EMA (European Medicines Agency)

mylan pharmaceuticals limited - atazanavir (as sulfate) - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - atazanavir Майлана, uvedeni zajedno s malom dozom ritonavir, indiciran za liječenje hiv-1 zaraženih odraslih i pedijatrijska bolesnika 6 godina i stariji u kombinaciji s drugim antiretrovirusne lijekove. na osnovu вирусологических i kliničkih podataka kod odraslih pacijenata, nikakvu korist ne očekuje se da će u bolesnika s sojeva rezistentnih na više inhibitori proteaze (≥ 4 mutacije pi). dostupne su vrlo ograničene podatke od djece u dobi od 6 do manje od 18 godina. izbor atazanavir Майлана u liječenju iskusni, odrasli i педиатрические pacijenti moraju se temeljiti na individualnoj virusne rezistencije i povijesti liječenja pacijenta .

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck sharp & dohme b.v. - caspofungin (as acetate) - candidiasis; aspergillosis - antimikotika za sustavnu uporabu - treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin b, lipid formulations of amphotericin b and / or itraconazole. refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as candida or aspergillus) in febrile, neutropaenic adult or paediatric patients.

Europska Unija - hrvatski - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dislipidemije - sredstva za modifikaciju lipida - cholib je indiciran kao dodatna terapija dijeti i tjelovježbi u odraslih bolesnika visokim s mješovitim dislipidemijom za smanjenje triglicerida i povećanje razine hdl c kad ldl c razinama adekvatno upravlja pomoću odgovarajuće doze monoterapije simvastatinom.

Europska Unija - hrvatski - EMA (European Medicines Agency)

taw pharma (ireland) limited - klopidogrel hidroklorid - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - antitrombotska sredstva - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Europska Unija - hrvatski - EMA (European Medicines Agency)

teva pharma b.v. - tableta - parkinsonova bolest - antiparkinsonski lijekovi - entacapone je indiciran kao dodatak standardnim pripremama levodope / benserazide ili levodope / carbidopa u odraslih bolesnika s parkinsonovom bolesti i kraju doze motoričke fluktuacije, koji mogu biti stabilizirani te kombinacije.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - danmavir - hiv infekcije - antivirusni lijekovi za sustavnu uporabu - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Europska Unija - hrvatski - EMA (European Medicines Agency)

janssen-cilag international nv - bosentan (as monohydrate) - hypertension, pulmonary; scleroderma, systemic - drugi antihipertenzivi sredstva - liječenje plućne arterijske hipertenzije (pah) za poboljšanje sposobnosti vježbanja i simptoma u bolesnika s funkcionalnom klasom svjetske zdravstvene organizacije (who) iii. učinkovitost je prikazan u:primarna (idiopatska i nasljedna) fuj;fuj sekundarne склеродермии bez značajnog интерстициальные bolesti pluća;lag, povezana sa urođenim sistem-na-plućna шунтов i eisenmenger fiziologije. neka poboljšanja su također je prikazano u bolesnika s lag, koji funkcionalna klasa ii. stayveer također je istakao smanjenje broja novih digitalne ulkusa kod pacijenata sa sistemske склеродермией i stalnom digitalni-peptičkog ulkusa.